[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100400832":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":21,"centralContacts":26,"locations":36,"responsibleParty":54,"collaborators":21,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":21,"eligibilityCriteria":64,"healthyVolunteers":60,"sex":65,"minAge":66,"maxAge":67,"enrollmentInfo":68,"targetDuration":21,"studyType":71,"phases":72,"briefSummary":74,"conditions":75,"keywords":21,"overallStatus":39,"whyStopped":21,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"First Affiliated Hospital of Fujian Medical University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Experimental: 68Ga-DOTA\u002FNOTA-FAPI-04","EXPERIMENTAL","Each subject receive a single intravenous injection of 68Ga-DOTA\u002FNOTA-FAPI-04, and undergo PET\u002FCT imaging within the specificed time.",[13,14],"Drug: 68Ga-DOTA\u002FNOTA-FAPI-04","Diagnostic Test: PET\u002FCT scan",[16,22],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":21},"DRUG","68Ga-DOTA\u002FNOTA-FAPI-04","Each patient receive a single intravenous injection of 68Ga-DOTA\u002FNOTA-FAPI-04, and undergo PET\u002FCT scan within specified time.",[9],null,{"type":23,"name":24,"description":24,"armGroupLabels":25,"otherNames":21},"DIAGNOSTIC_TEST","PET\u002FCT scan",[9],[27,32],{"name":28,"role":29,"phone":30,"phoneExt":21,"email":31},"Weibing Miao, MD","CONTACT","86-0591-87981618","miaoweibing@126.com",{"name":33,"role":29,"phone":34,"phoneExt":21,"email":35},"Shan Zheng, MD","86-0591-87981619","zhengshan1982@126.com",[37],{"facility":38,"status":39,"city":40,"state":41,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"The First Affiliated Hospital of Fujian Medical University","RECRUITING","Fuzhou","Fujian","350005","China","CN",{"type":46,"coordinates":47},"Point",[48,49],119.30611,26.06139,{"lat":49,"lon":48},[52,53],{"name":28,"role":29,"phone":30,"phoneExt":21,"email":31},{"name":33,"role":29,"phone":34,"phoneExt":21,"email":35},{"type":55,"investigatorFullName":56,"investigatorTitle":57,"investigatorAffiliation":5,"oldNameTitle":21,"oldOrganization":21},"PRINCIPAL_INVESTIGATOR","Weibing Miao, PhD","Director, Department of Nuclear Medicine","100400832","early-phase-1-68ga-fapi-petct-in-patients-with-various-types-of-cancer-100400832",false,"NCT04499365","68Ga-FAPI PET\u002FCT in Patients With Various Types of Cancer","68Ga-DOTA\u002FNOTA-FAPI-04 PET\u002FCT in Patients With Various Types of Cancer","Inclusion Criteria:\n\n* (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled 68Ga-DOTA\u002FNOTA-FAPI-04 PET\u002FCT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.\n\nExclusion Criteria:\n\n* (i) patients with non-malignant lesions; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.","ALL","18 Years","90 Years",{"count":69,"type":70},500,"ESTIMATED","INTERVENTIONAL",[73],"EARLY_PHASE1","To evaluate the potential usefulness of 68Ga-DOTA\u002FNOTA-FAPI-04 positron emission tomography\u002Fcomputed tomography (PET\u002FCT) for the diagnosis of primary and metastatic lesions in various types of cancer.",[76,77,78],"Tumor","Positron-Emission Tomography","Metastasis","2026-07-19",{"date":81,"type":82},"2026-07-21","ACTUAL",{"date":84,"type":82},"2020-08-15",{"date":86,"type":70},"2027-12-30",{"name":5,"class":6},1]